东方量化多策略混合A（006785）成立日期2019年2月22日，最新规模2878.44万。今年以来收益 32.45%，同类排名2692/8147；近一年收益24.18%，同类排名3043/8056；成立以来亏损2.63%。 东方量化多策略混合A（006785）基金经理为盛泽、王怀勋。 截至发稿，盛泽累计任职时间7年93天，现任基金资产总规模11.67亿元，任职期间最佳基金回报 132.76%， 任职期间最差基金回报-20.29%。 11月11日，亨迪药业涨5.08%，截至发稿，报16.34元/股，成交4.15亿元，换手率6.34%，总市值68.24亿 元。 资料显示，湖北亨迪药业股份有限公司位于湖北省荆门市掇刀区杨湾路122号，成立日期1995年12月29 日，上市日期2021年12月22日，公司主营业务涉及化学原料药及制剂产品的研发、生产和销售。主营业 务收入构成为：非甾体抗炎类68.06%，心血管类16.08%，其他8.86%，抗肿瘤类6.99%。 从基金十大重仓股角度 数据显示，东方基金旗下1只基金重仓亨迪药业。东方量化多策略混合A（006785）三季度持有股数1.16 万股，占基金净值比例为0.43 ...

Group 1 - The stock price of North China Pharmaceutical closed at 6.83 yuan on August 5, 2025, down 0.87% from the previous trading day [1] - The company reported a trading volume of 201,300 lots and a transaction amount of 138 million yuan on the same day [1] - North China Pharmaceutical specializes in the research, production, and sales of chemical raw materials and formulations, covering various therapeutic areas including anti-infection, cardiovascular, vitamins, and nutritional health products [1] Group 2 - For the first half of 2025, the company expects to achieve a net profit of 123.5 million yuan, representing a year-on-year increase of 72% [1] - The anticipated growth in the mid-year report is primarily attributed to an increase in main business revenue and cost control [1] - The net profit attributable to shareholders of the listed company is expected to increase by approximately 51.52 million yuan year-on-year for the period of January to June [1] Group 3 - On August 5, 2025, the net outflow of main funds was 23.976 million yuan, with a cumulative net outflow of 107.8 million yuan over the past five trading days [1]